| Item Type | Name |
|
Concept
|
Antibodies, Neoplasm
|
|
Concept
|
Antibodies, Anti-Idiotypic
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Protein Engineering
|
|
Concept
|
Antibodies, Bispecific
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Antibodies, Monoclonal, Murine-Derived
|
|
Concept
|
Antibodies, Neutralizing
|
|
Concept
|
Antibodies
|
|
Academic Article
|
The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
|
|
Academic Article
|
The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
|
|
Academic Article
|
Cancer-associated retinopathy in a patient with non-small-cell lung carcinoma.
|
|
Academic Article
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
|
|
Academic Article
|
Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma.
|
|
Academic Article
|
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
|
|
Academic Article
|
Therapeutic targeting of receptor tyrosine kinases in lung cancer.
|
|
Academic Article
|
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
|
|
Academic Article
|
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.
|
|
Academic Article
|
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
|
|
Academic Article
|
Role of MetMAb (OA-5D5) in c-MET active lung malignancies.
|
|
Academic Article
|
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.
|
|
Academic Article
|
EphB4 as a therapeutic target in mesothelioma.
|
|
Academic Article
|
Teaching Video NeuroImages: myokymia and nerve hyperexcitability as components of Morvan syndrome due to malignant thymoma.
|
|
Academic Article
|
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.
|
|
Academic Article
|
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
|
|
Academic Article
|
A new hope for precision medicine.
|
|
Academic Article
|
AXL mediates resistance to cetuximab therapy.
|
|
Academic Article
|
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
|
|
Academic Article
|
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
|
|
Academic Article
|
Engineering Synthetic Antibody Inhibitors Specific for LD2 or LD4 Motifs of Paxillin.
|
|
Academic Article
|
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
|
|
Academic Article
|
Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
|
|
Academic Article
|
Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone.
|
|
Academic Article
|
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors.
|
|
Academic Article
|
Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report.
|
|
Academic Article
|
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
|
|
Academic Article
|
RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells.
|
|
Academic Article
|
Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.
|
|
Academic Article
|
Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.
|
|
Academic Article
|
Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC).
|
|
Academic Article
|
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
|
|
Grant
|
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
|
|
Grant
|
PAXILLIN--AN ONCOGENE ACTIVATED PROTEIN
|